David E Cohn, MD
Leadership Title: Stuart M. Sloan - Larry J. Copeland, MD, Chair in Gynecologic Oncology
Academic Title: Professor in the College of Medicine
Research Program: Translational Therapeutics
About Me
More info forI am the interim CEO of the James Cancer Hospital and Solove Research Institute, where I also serve as chief medical officer. I am a professor in the Department of Obstetrics and Gynecology, Division of Gynecologic Oncology at The Ohio State University College of Medicine, and I hold the Stuart M. Sloan – Larry J. Copeland, MD, Chair in Gynecologic Oncology. I have been on Ohio State’s medical faculty since 2001. I maintain a clinical practice that includes both medical and surgical treatment of gynecologic cancers, and I have been widely recognized by my peers for excellence in both clinical practice and teaching. In addition, I have been consistently named to the Castle Connolly list of top doctors. At Ohio State’s Comprehensive Cancer Center, I am a member of the Translational Therapeutics Program. My research focuses on identifying biomarkers for early detection and prevention of ovarian cancer, as well as on the genetics of endometrial (uterine) cancer. I have published nearly 300 manuscripts in scientific journals and several book chapters, and I hold two patents – one for early detection of ovarian cancer and the other for a novel vaccination strategy for treating this disease. Nationally, I have served as co-chair of the National Cancer Institute NRG Oncology’s Cancer Care Delivery Committee, and as president of the Society of Gynecologic Oncology (SGO). In January 2022 I became editor-in-chief of the journal Gynecologic Oncology, an international journal devoted to the publication of clinical and investigative articles about tumors of the female reproductive tract. I had been a deputy editor for that journal – the official publication of the SGO – since 2011. After graduating from the University of Michigan, I earned my MD from the Georgetown University School of Medicine in Washington, D.C. I then completed my residency at the University of Washington Medical Center in Seattle and my fellowship training in gynecologic oncology at Washington University School of Medicine in St. Louis, Missouri. I received my MBA from the Fisher College of Business at Ohio State.
Clinical Expertise
More info for- Cervical Cancer
- Gynecologic Cancers
- Reproductive Health
- Women's Health
- Vaginal Cancers
- Endometrial Cancers
- Ovarian Cancers
- Vulvar Cancers
- Uterine Cancers
- Minimally Invasive Surgical Procedures
- Robotics
- Peritoneal Cancers
Research Interests
More info for- Body Mass Index
- Microsatellite Instability
- Carcinoma
- Neoplasms
- Endometrial Neoplasms
- Adenocarcinoma
- Neoplasm Metastasis
- Uterine Cervical Neoplasms
- Ovarian Neoplasms
- Colorectal Neoplasms, Hereditary Nonpolyposis
Where I See Patients
More info forThe James Gynecologic Oncology Mill Run
3651 Ridge Mill Drive Hilliard, Ohio 43026 614-293-3873 Location InformationEducation & Training
More info forMedical School
- Georgetown University School of Medicine
3900 Nw Reservoir Rd, Washington, DC
Internship - Obstetrics & Gynecology
- University of Washington Medical Center
1959 Ne Pacific St, Seattle, WA
Residency - Obstetrics & Gynecology
- University of Washington Medical Center
1959 Ne Pacific St, Seattle, WA
Fellowship - Gynecologic Oncology
- Washington University School of Medicine
660 S Euclid Ave, St. Louis, MO
- Georgetown University School of Medicine
Academic Office & Contact Information
More info forAcademic Office:
320 W 10th Ave
Columbus, Ohio 43210-1280Email:
cohn.30@osu.eduReviews
More info forPatient Satisfaction Review
The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our
Patient Satisfaction Survey page The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.
Videos
More info forPublications
More info forOctober 16, 2024Obesity-induced extracellular vesicles proteins drive the endometrial cancer pathogenesis: therapeutic potential of HO-3867 and Metformin.
Sakaue T, Dorayappan KDP, Zingarelli R, Khadraoui W, Anbalagan M, Wallbillich J, Bognar B, Wanner R, Cosgrove C, Suarez A, Koga H, Maxwell GL, O'Malley DM, Cohn DE, Selvendiran K
Oncogene
April 1, 2024Learning to lead: The evolution of a pilot leadership curriculum for gynecologic oncology fellows at the Ohio State University.
Levine MD, Wagner VM, Riedinger CJ, Khadraoui W, Haight PJ, Morton M, Barrington DA, Calo CA, Castaneda AV, Lightfoot M, Chalif J, Gonzalez A, Cohn DE
Gynecol Oncol Rep
April 1, 2024Retraction notice to "Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer" [Gynecologic Oncology 183 (2024) 78-84].
Riedinger CJ, Barrington DA, Nagel CI, Khadraoui WK, Haight PJ, Tubbs C, Backes FJ, Cohn DE, O'Malley DM, Copeland LJ, Chambers LM
Gynecol Oncol
March 29, 2024Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer.
Riedinger CJ, Barrington DA, Nagel CI, Khadraoui WK, Haight PJ, Tubbs C, Backes FJ, Cohn DE, O'Malley DM, Copeland LJ, Chambers LM
Gynecol Oncol
March 2, 2024Reply to "Mismatch repair and microsatellite instability-Recommendation for an optimal test strategy".
Riedinger CJ, Esnakula A, Haight PJ, Suarez AA, Chen W, Gillespie J, Villacres A, Chassen A, Cohn DE, Goodfellow PJ, Cosgrove CM
Cancer
February 7, 2024Authentic leadership in action: Experience gained from a gynecologic oncology fellowship leadership curriculum.
Levine MD, Wagner VM, Riedinger CJ, Khadraoui W, Haight PJ, Morton M, Cohn DE
Gynecol Oncol
February 1, 2024ISG15 mediates the function of extracellular vesicles in promoting ovarian cancer progression and metastasis.
Dorayappan KDP, Wagner V, Park D, Newcomer MM, Lightfoot MDS, Kalaiyarasan D, Sakaue T, Khadraoui W, Yu L, Wang QE, Maxwell GL, O'Malley D, Pollock RE, Cohn DE, Selvendiran K
J Extracell Biol
January 25, 2024An SGO commentary: U.S. News and World Report gynecologic oncology procedural ratings-Do they reflect high-quality care?
Fader AN, Ko EM, Pollock BD, Blank SV, Cohn DE, Huh W, Shahin MS, Dowdy SC
Gynecol Oncol
January 24, 2024Changes in prospectively collected patient-reported outcomes among women with incident endometrial cancer.
Sinnott JA, Torkashvand E, Meade CE, Salani R, Vetter MH, Hall B, Skolnick R, Bixel KL, Cohn DE, Cosgrove CM, Copeland LJ, Hebert C, Felix AS
J Cancer Surviv
January 22, 2024Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistance.
Levine MD, Wang H, Sriram B, Khan A, Senter L, McLaughlin EM, Bixel KL, Chambers LM, Cohn DE, Copeland LJ, Cosgrove CM, Nagel CI, O'Malley DM, Backes FJ
Gynecol Oncol
December 7, 2023Deep learning-based segmentation of multisite disease in ovarian cancer.
Buddenkotte T, Rundo L, Woitek R, Escudero Sanchez L, Beer L, Crispin-Ortuzar M, Etmann C, Mukherjee S, Bura V, McCague C, Sahin H, Pintican R, Zerunian M, Allajbeu I, Singh N, Sahdev A, Havrilesky L, Cohn DE, Bateman NW, Conrads TP, Darcy KM, Maxwell GL, Freymann JB, Öktem O, Brenton JD, Sala E, Schönlieb CB
Eur Radiol Exp
October 18, 2023Intraluminal tumor cells and prognostic accuracy of endometrial cancer stage criteria: A multi-institution study.
Felix AS, Sinnott JA, Cohn DE, Duggan MA, Havrilesky LJ, Olawaiye AB, Mariani A, Rodriquez M, Brett MA, Dinoi G, Meade CE, Hall B, Goldfeld E, Elishaev E, Sherman ME, Suarez AA
Gynecol Oncol
September 26, 2023Characterization of mismatch-repair (MMR)/microsatellite instability (MSI)-discordant endometrial cancers.
Riedinger CJ, Esnakula A, Haight PJ, Suarez AA, Chen W, Gillespie J, Villacres A, Chassen A, Cohn DE, Goodfellow PJ, Cosgrove CM
Cancer
September 21, 2023The impact of antibiotic and proton pump inhibitor use at the time of adjuvant platinum-based chemotherapy on survival in patients with endometrial cancer.
Haight PJ, Kistenfeger Q, Riedinger CJ, Khadraoui W, Backes FJ, Bixel KL, Copeland LJ, Cohn DE, Cosgrove CM, O'Malley DM, Nagel CI, Spakowicz DJ, Chambers LM
Gynecol Oncol
July 1, 2023Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study.
Praiss AM, Miller A, Smith J, Lichtman SM, Bookman M, Aghajanian C, Sabbatini P, Backes F, Cohn DE, Argenta P, Friedlander M, Goodheart MJ, Mutch DG, Gershenson DM, Tewari KS, Wenham RM, Wahner Hendrickson AE, Lee RB, Gray H, Secord AA, Van Le L, O'Cearbhaill RE
Gynecol Oncol
May 11, 2023Tissue factor as a novel diagnostic target for early detection of ovarian cancer using ultrasound microbubbles.
Newcomer MM, Dorayappan KDP, Wagner V, Suarez AA, Calo CA, Kalmar EL, Maxwell GL, O'Malley D, Cohn DE, Tweedle MF, Selvendiran K
Gynecol Oncol
May 4, 2023The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study.
Sia TY, Tew WP, Purdy C, Chi DS, Menzin AW, Lovecchio JL, Bookman MA, Cohn DE, Teoh DG, Friedlander M, Bender D, Mutch DG, Gershenson DM, Tewari KS, Wenham RM, Wahner Hendrickson AE, Lee RB, Gray HJ, Secord AA, Van Le L, Lichtman SM
Gynecol Oncol
April 8, 2023Glassy cell carcinoma of the cervix: Findings from a combined National Cancer Database analysis and single institution review of treatment patterns and outcomes.
Levine MD, Barrington DA, Meade CE, Lammers SM, McLaughlin EM, Suarez AA, Backes FJ, Copeland LJ, O'Malley DM, Cosgrove CM, Cohn DE, Nagel CI, Felix AS, Bixel KL
Gynecol Oncol
April 1, 2023Use of the Khorana score to predict venous thromboembolism in patients undergoing chemotherapy for uterine cancer.
Piver RN, Wagner VM, Levine MD, Backes FJ, Chambers LJ, Cohn DE, Copeland LJ, Cosgrove CM, Nagel CI, O'Malley DM, Bixel KL
Gynecol Oncol Rep
April 1, 2023Recurrence rate in early-stage epithelial ovarian cancer: Is there a role for upfront maintenance with PARP inhibitors in stages I and II?
Levine MD, O'Malley DM, Haight PJ, Senter L, Wagner V, Bixel KL, Cohn DE, Copeland LJ, Cosgrove CM, McLaughlin EM, Backes FJ
Gynecol Oncol Rep
February 1, 2023Dietary omega-3 fatty acids and endometrial cancer risk in the Epidemiology of Endometrial Cancer Consortium: An individual-participant meta-analysis.
Brasky TM, Hade EM, Cohn DE, Newton AM, Petruzella S, O'Connell K, Bertrand KA, Cook LS, De Vivo I, Du M, Freudenheim JL, Friedenreich CM, Goodman MT, Gorzelitz J, Ibiebele TI, Krogh V, Liao LM, Lipworth L, Lu L, McCann S, O'Mara TA, Palmer JR, Ponte J, Prizment A, Risch H, Sandin S, Schouten LJ, Setiawan VW, Shu XO, Trabert B, van den Brandt PA, Webb PM, Wentzensen N, Wilkens LR, Wolk A, Yu H, Neuhouser ML
Gynecol Oncol
January 1, 2023Epigenetic MMR defect identifies a risk group not accounted for through traditional risk stratification algorithms in endometrial cancer.
Riedinger CJ, Brown M, Haight PJ, Backes FJ, Cohn DE, Goodfellow PJ, Cosgrove CM
Front Oncol
December 24, 2022Postoperative Venous Thromboembolism Risk Stratification in Patients with Uterine Cancer.
Wagner VM, Piver RN, Levine MD, Backes FJ, Chambers LJ, Cohn DE, Copeland LJ, Cosgrove CM, Nagel CI, O'Malley DM, Bixel KL
Am J Obstet Gynecol
December 7, 2022Targeting TMEM205 mediated drug resistance in ovarian clear cell carcinoma using oncolytic virus.
Saini U, Smith BQ, Dorayappan KDP, Yoo JY, Maxwell GL, Kaur B, Konishi I, O'Malley D, Cohn DE, Selvendiran K
J Ovarian Res
September 22, 2022Clinical outcomes in patients with COVID-19 and gynecologic cancer: A society of gynecologic oncology COVID-19 and gynecologic cancer registry study.
Glaser GE, Lara OD, Pothuri B, Grimaldi CG, Prescott LS, Mastroyannis SA, Kim S, ElNaggar AC, Torres D, Conrad LB, McGree M, Weaver A, Huh WK, Cohn DE, Yamada SD, Fader AN
Gynecol Oncol
September 22, 2022The contemporary presentation and diagnosis of endometrial cancer recurrence: When, where, and how?
Riedinger CJ, Patterson JM, Backes FJ, O'Malley D, Bixel KL, Copeland LJ, Cohn DE, Goodfellow PJ, Cosgrove CM
Gynecol Oncol
August 2, 2022Less is more: Clinical utility of postoperative labs following minimally invasive hysterectomy for endometrial cancer.
Lightfoot MDS, Felix AS, Calo CA, Hosmer-Quint JT, Taylor KL, Brown MB, Salani R, Copeland LJ, O'Malley DM, Bixel KL, Cohn DE, Fowler JM, Backes FJ, Cosgrove CM
Am J Obstet Gynecol
August 1, 2022High pre-treatment neutrophil-to-lymphocyte ratio as a prognostic marker for worse survival in patients with recurrent/metastatic cervical cancer treated with immune checkpoint inhibitors.
Calo CA, Barrington DA, Brown M, Gonzalez L, Baek J, Huffman A, Benedict J, Backes F, Chambers L, Cohn D, Copeland L, Cosgrove C, Nagel C, O'Malley D, Bixel K
Gynecol Oncol Rep
July 23, 2022Racial and ethnic disparities in readmission risk following the surgical management of endometrial cancer.
Barrington DA, Meade CE, Cosgrove CM, Cohn DE, Felix AS
Gynecol Oncol
March 10, 2022More than treatment refusal: a National Cancer Database analysis of adjuvant treatment refusal and racial survival disparities among women with endometrial cancer.
Barrington DA, Sinnott JA, Nixon D, Padamsee TJ, Cohn DE, Doll KM, Donneyong MM, Felix AS
Am J Obstet Gynecol
November 1, 2021Prehabilitation for medically frail patients undergoing surgery for epithelial ovarian cancer: a cost-effectiveness analysis.
Dholakia J, Cohn DE, Straughn JM, Dilley SE
J Gynecol Oncol
November 1, 2021Up-Front Multigene Panel Testing for Cancer Susceptibility in Patients With Newly Diagnosed Endometrial Cancer: A Multicenter Prospective Study.
Levine MD, Pearlman R, Hampel H, Cosgrove C, Cohn D, Chassen A, Suarez A, Barrington DA, McElroy JP, Waggoner S, Nakayama J, Billingsley C, Resnick K, Andrews S, Singh S, Jenison E, Clements A, Neff R, Goodfellow PJ, Ohio Prevention and Treatment of Endometrial Cancer Initiative Study Group
JCO Precis Oncol
November 1, 2021Wound complications following vulvar excision for nonmalignant lesions.
Boyles GP, Weaver AM, Cohn DE, Backes FJ, Copeland LJ, Bixel KL, Fowler JM, O'Malley DM, Cosgrove CM
AJOG Glob Rep
October 29, 2021Aberrant expression of TMEM205 signaling promotes platinum resistance in ovarian cancer: An implication for the antitumor potential of DAP compound.
Calo CA, Smith BQ, Dorayappan KDP, Saini U, Lightfoot M, Wagner V, Kalaiyarasan D, Cosgrove C, Wang QE, Maxwell GL, Kálai T, Kuppusamy P, Cohn DE, Selvendiran K
Gynecol Oncol
August 17, 2021Endometrial Cancer: Who lives, who dies, can we improve their story?
Cosgrove CM, Backes FJ, O'Malley D, Bixel KL, Suarez AA, Fowler JM, Copeland LJ, Goodfellow PJ, Cohn DE
Oncologist
August 1, 2021NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021.
Abu-Rustum NR, Yashar CM, Bradley K, Campos SM, Chino J, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Diver E, Fisher CM, Frederick P, Gaffney DK, George S, Giuntoli R, Han E, Howitt B, Huh WK, Lea J, Mariani A, Mutch D, Nekhlyudov L, Podoll M, Remmenga SW, Reynolds RK, Salani R, Sisodia R, Soliman P, Tanner E, Ueda S, Urban R, Wethington SL, Wyse E, Zanotti K, McMillian NR, Motter AD
J Natl Compr Canc Netw
July 13, 2021Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer.
Backes FJ, Wei L, Chen M, Hill K, Dzwigalski K, Poi M, Phelps M, Salani R, Copeland LJ, Fowler JM, Cohn DE, Bixel K, Cosgrove C, Hays J, O'Malley D
Gynecol Oncol
June 17, 2021Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis.
Barrington DA, Haight PJ, Calhoun C, Tubbs C, Cohn DE, Bixel KL
Gynecol Oncol
January 1, 2021Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients.
Hampel H, Pearlman R, de la Chapelle A, Pritchard CC, Zhao W, Jones D, Yilmaz A, Chen W, Frankel WL, Suarez AA, Cosgrove C, Backes F, Copeland L, Fowler J, O'Malley D, Salani R, McElroy JP, Stanich PP, Goodfellow P, Cohn DE
Gynecol Oncol
October 21, 2020Oncolytic HSV therapy modulates vesicular trafficking inducing cisplatin sensitivity and anti-tumor immunity.
Kaur B, Hong B, Chapa V, Saini U, Modgil P, Cohn DE, He G, Siddik ZH, Sood AK, Yan Y, Karuppaiyah S, Pei G, Zhao Z, Yoo JY
Clin Cancer Res
September 29, 2020Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209).
Miller DS, Filiaci VL, Mannel RS, Cohn DE, Matsumoto T, Tewari KS, DiSilvestro P, Pearl ML, Argenta PA, Powell MA, Zweizig SL, Warshal DP, Hanjani P, Carney ME, Huang H, Cella D, Zaino R, Fleming GF
J Clin Oncol
September 1, 2020Pathologic chemotherapy response score in epithelial ovarian cancer: Surgical, genetic, and survival considerations.
Barrington DA, Felix AS, Owda R, Suarez AA, Cohen DW, Senter L, Copeland LJ, Fowler JM, Backes FJ, Cohn DE, Bixel KL, O'Malley DM, Salani R, Cosgrove CM
Surg Oncol
August 17, 2020Evaluating the efficacy of enzalutamide and the development of resistance in a preclinical mouse model of type-I endometrial carcinoma.
Koivisto CS, Parrish M, Bonala SB, Ngoi S, Torres A, Gallagher J, Sanchez-Hodge R, Zeinner V, Nahhas GJ, Liu B, Cohn DE, Backes FJ, Goodfellow PJ, Chamberlin HM, Leone G
Neoplasia
August 4, 2020Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis.
Barrington DA, Tubbs C, Smith HJ, Straughn JM, Senter L, Cohn DE
Int J Gynecol Cancer
July 1, 2020Patient reported outcomes measures in gynecologic oncology: A primer for clinical use, part I.
Sisodia RC, Dewdney SB, Fader AN, Wethington SL, Melamed A, Von Gruenigen VE, Zivanovic O, Carter J, Cohn DE, Huh W, Wenzel L, Doll K, Cella D, Dowdy SC
Gynecol Oncol
July 1, 2020Patient reported outcomes measures in gynecologic oncology: A primer for clinical use, Part II.
Sisodia RC, Dewdney SB, Fader AN, Wethington SL, Melamed A, Von Gruenigen VE, Zivanovic O, Carter J, Cohn DE, Huh W, Wenzel L, Doll K, Cella D, Dowdy SC
Gynecol Oncol
June 9, 2020Where you live matters: A National Cancer Database study of Medicaid expansion and endometrial cancer outcomes.
Barrington DA, Sinnott JA, Calo C, Cohn DE, Cosgrove CM, Felix AS
Gynecol Oncol
June 1, 2020NCCN Guidelines Insights: Cervical Cancer, Version 1.2020.
Abu-Rustum NR, Yashar CM, Bean S, Bradley K, Campos SM, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Fisher CM, Frederick P, Gaffney DK, Giuntoli R, Han E, Huh WK, Lurain Iii JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Sisodia R, Tillmanns T, Ueda S, Urban R, Wyse E, McMillian NR, Motter AD
J Natl Compr Canc Netw
May 23, 2020Chemotherapy directly followed by PARP inhibition as an alternative to surgery in patients with BRCA- mutated ovarian cancer - a potential management strategy in the era of COVID-19.
Vetter MH, Smrz SA, Copeland LJ, Cohn DE
Am J Obstet Gynecol
Consulting and Related Relationships
More info forAt The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Cohn has reported no relationships with companies or entities.
Patient Comments
Dr. Cohen and his staff are the greatest there's no other doctor. I don't wanna be with other than Dr. Cohen I was very lucky to having as my Doctor I would recommend him to anyone that have a problem with cancer
Always treats my question as important
Professional and compassionate interaction and care
Dr. Cohn and Katie are a great team.
Very professional friendly personable
All "Very Good"
Dr. Cohn was wonderful, very understanding & helpful threw everything. He's my hero.
Dr. Cohn has always taken time to answer all my questions and concerns.
Dr. Cohn answered all my questions and concerns thoroughly. He treated me with kindness, understanding and respect. I appreciate him treating me like a human being, not a number, who is facing surgery.
Dr asked me several times Are you comfortable? And worries or questionsVery nice and professional
Have always been well taken care of.
Dr Cohn and his staff are a gift to patients and OSU. I just got my 10 yr mark of being cancer-free. I never doubted for a moment anything he told me about my diagnosis or tx.
I left the office feeling so relieved about my options.
I was assigned Dr. David Cohn as my provider in 2013. He still sees me personally! I am blessed to have such a great team to give me all the options available - (+ allow me to change my mind occasionally!).